Share Twitter LinkedIn Facebook Email Dr. Jack West, Swedish Cancer Institute, discusses the anti-angiogenic agent bevacizumab (Avastin) and the trial evidence of its efficacy for non-squamous NSCLC. Advertisement
ASCO 2025: Lung Cancer Immunotherapy Breakthroughs from the Immuno-Oncology Symposium Lung Cancer Treatment 4 Mins Read